Wall Street brokerages expect that argenx SE – (NASDAQ:ARGX) will post sales of $17.38 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for argenx’s earnings, with the highest sales estimate coming in at $23.49 million and the lowest estimate coming in at $9.72 million. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that argenx will report full year sales of $69.11 million for the current year, with estimates ranging from $22.31 million to $95.75 million. For the next financial year, analysts expect that the business will report sales of $115.14 million, with estimates ranging from $51.55 million to $190.24 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow argenx.
argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.72) by ($0.15). The company had revenue of $21.15 million during the quarter, compared to analyst estimates of $18.08 million.
Shares of argenx stock traded up $2.00 during trading on Monday, hitting $157.96. 93,838 shares of the stock traded hands, compared to its average volume of 124,959. The stock has a market cap of $6.67 billion, a P/E ratio of -33.40 and a beta of 1.05. The company has a fifty day moving average price of $145.35 and a two-hundred day moving average price of $146.66. argenx has a twelve month low of $103.75 and a twelve month high of $169.50.
A number of institutional investors have recently modified their holdings of the business. AJO LP acquired a new stake in argenx in the 4th quarter worth $29,000. IFP Advisors Inc acquired a new stake in argenx during the fourth quarter worth about $51,000. Fieldpoint Private Securities LLC bought a new position in argenx during the fourth quarter valued at about $63,000. US Bancorp DE acquired a new position in argenx in the 4th quarter valued at approximately $67,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of argenx by 53.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 495 shares of the company’s stock worth $79,000 after acquiring an additional 173 shares during the period. 56.23% of the stock is owned by hedge funds and other institutional investors.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Further Reading: Market Indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.